Mark Silvert, MD
Urology · Vallejo
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location
Looking this up.
Hospitals listed: Alta Bates Summit Medical Center · Sutter Medical Center, Sacramento · Sutter Solano Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Silvert’s office at (510) 235-1137 to ask if they take your plan before you enroll.
California Medical Board record
Licence G23121 · Current
Licensed to practise in California · since 1972 · expires 2027-02-28 · University of Chicago, Pritzker School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Alta Bates Summit Medical CenterOakland, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Death rate among surgical inpatients with serious treatable complications: 130.09 (87.72 to 172.46) · 109 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.274, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.227, Oct 2024 – Sep 2025
- Sutter Medical Center, SacramentoSacramento, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 79% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 13.9 (12 to 15.9) · 992 cases, Jan 2024 – Dec 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.066, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.335, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.215, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.46, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.253, Oct 2024 – Sep 2025
- Sutter Solano Medical CenterVallejo, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 61% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.272, Oct 2024 – Sep 2025
See every measure and the patient survey for Alta Bates Summit Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 4 better, 3 the same, 0 worse of 7 measures. Readmissions: 3 better, 6 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 130.09 (87.72 to 172.46) · 109 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.274 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.227 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1 (0.06 to 1.94) · 1,209 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.88 (0.6 to 1.16) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.9 · 105 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.8 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 447 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.7 · 341 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.2 · 381 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 2,811 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.31) · 7,167 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,659 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.93 (0.92 to 4.94) · 1,668 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.25 (0 to 2.75) · 580 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.67 (1.19 to 4.15) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.17 (0.33 to 12.02) · 633 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 8.11 (4.67 to 11.55) · 619 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.07) · 309 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.39 (0 to 0.96) · 6,085 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.8 · 217 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.724 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.425 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.716 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 12.7 · 416 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.6 · 606 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -30.4 · 359 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -31.8 · 555 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -14.4 · 358 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16 · 382 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.1 (3.2 to 8.2) · 25 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.8 (7.3 to 16) · 25 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.5 · 232 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.9 · 56 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 152 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14.8 (11.1 to 20) · 251 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 579 cases | No different | Jan 2024 – Dec 2024 |
What patients said (535 patients answered, 18% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 73% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Sutter Medical Center, Sacramento
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 0 better, 9 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.9 (12 to 15.9) · 992 cases | Worse | Jan 2024 – Dec 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.066 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.335 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.215 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.46 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.253 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.12 (0.29 to 1.94) · 2,408 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.99 (0.78 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.68 (126.66 to 206.71) · 180 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.4 · 292 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.7 · 143 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.2 · 359 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.8 · 543 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.9 · 425 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.4 · 441 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 5,216 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.11 (0 to 0.29) · 9,948 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.1 to 0.45) · 10,968 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.04 (1.53 to 4.56) · 3,983 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.33 (0.2 to 2.46) · 2,033 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.78 (1.69 to 3.87) · 3,594 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.79 (6.29 to 13.29) · 2,100 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.62 (4.04 to 9.2) · 2,018 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.63 (0.29 to 2.98) · 867 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.54 (0.07 to 1.01) · 8,613 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.3 · 294 cases | None | Apr 2023 – Mar 2025 |
| SSI - Abdominal HysterectomyInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 598 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.9 · 924 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 8.5 · 488 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -18.3 · 638 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 24.4 · 443 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.7 · 600 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.9 (3.9 to 6.1) · 992 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 298 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9 · 249 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 250 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.3 (8.7 to 14.6) · 1,326 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.3) · 934 cases | No different | Jan 2024 – Dec 2024 |
What patients said (700 patients answered, 20% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 84% |
| Doctors "always" explained things so they could understand | 75% |
| Doctors "always" listened carefully | 77% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 49% |
| "YES", patients would definitely recommend the hospital | 79% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
See every measure and the patient survey for Sutter Solano Medical Center
Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 0 better, 8 the same, 1 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.272 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.93 (0 to 1.95) · 374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.99 (0.6 to 1.38) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 162.36 (106.6 to 218.11) · 31 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 7.3 · 77 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.9 · 28 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.2 · 113 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 16.2 · 154 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.3 · 65 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.6 · 960 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.41) · 2,268 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.04 to 0.46) · 2,327 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.7 (0.38 to 5.03) · 594 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.61 (0 to 3.31) · 285 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.13 (0.47 to 3.78) · 581 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.1 (0 to 16.32) · 302 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.77 (3.74 to 11.8) · 275 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.72 (0.21 to 3.24) · 114 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.59 (0 to 1.48) · 1,998 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.8 · 171 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.4 · 142 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 0.8 · 131 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 33 · 162 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18 · 160 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.5 (3.6 to 8.5) · 42 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10 (6.8 to 14.4) · 42 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.7 · 165 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 76 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14.2 (10.6 to 18.9) · 322 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.8 to 1.6) · 84 cases | No different | Jan 2024 – Dec 2024 |
What patients said (355 patients answered, 17% of those asked)
| Cleanliness | 2 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 63% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 78% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 85% |
| Yes, staff "did" give patients information about help after discharge | 84% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 64% |
| Staff "always" explained new medications | 69% |
| Nurses "always" explained things so they could understand | 72% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 61% |
| Staff "always" explained possible side effects | 45% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Original Medicare doctor bills
$146,960
Medicare paid this office $146,960 for 412 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Short return visit (20+ min) | 259 | $25,132 | $62 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 18 | $16,140 | None |
| New patient visit (45+ min) | 65 | $9,569 | $147 |
| Diagnostic exam of bladder and urethra using an endoscope | 35 | $9,431 | $192 |
| Short return visit | 121 | $8,302 | $52 |
See all 12 services
| Short return visit (20+ min) | 259 | $25,132 | $62 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 18 | $16,140 | None |
| New patient visit (45+ min) | 65 | $9,569 | $147 |
| Diagnostic exam of bladder and urethra using an endoscope | 35 | $9,431 | $192 |
| Short return visit | 121 | $8,302 | $52 |
| Shock wave crushing of kidney stones | 11 | $6,084 | $553 |
| Return visit (30+ min) | 41 | $4,679 | $109 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 14 | $2,203 | $157 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 16 | $2,004 | $118 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 16 | $1,943 | $63 |
| Simple bladder irrigation and/or instillation | 21 | $1,855 | $71 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 18 | $1,187 | $26 |
Procedures Medicare counted
| Colonoscopy | 1-10 | None |
| Prostate resection | 11 | More than 58% of doctors who do this |
Who their Medicare patients are
412 Original Medicare patients in 2024. Average age 75 · Under 65 8% · 85 and older 18% · Women 16% · Also on Medicaid 46% · Health risk score 1.56. Above the middle of the specialty; the typical urology clinician is at 1.36.
Conditions among them: High blood pressure 75% · Diabetes 41% · Chronic kidney disease 41% · Cancer 33% · Coronary heart disease 24% · COPD 19% · Heart failure 18% · Atrial fibrillation 18% · Depression 18% · Dementia 11% · Stroke 11%.
The office billed $239,419, Medicare allowed $192,276 and paid $146,960; for 3,607 services of 62 kinds; $21,853 of it was for drugs given in the office and $125,107 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 412 | 3,607 | 75 | 1.56 | $239,419 | $146,960 |
| 2023 | 468 | 3,548 | 74 | 1.62 | $285,550 | $169,398 |
| 2022 | 489 | 3,901 | 74 | 1.49 | $336,359 | $193,313 |
| 2021 | 524 | 2,911 | 74 | 1.47 | $365,806 | $193,070 |
| 2020 | 517 | 2,783 | 73 | 1.60 | $353,028 | $190,813 |
| 2019 | 666 | 2,489 | 73 | 1.54 | $574,750 | $294,691 |
| 2018 | 679 | 2,376 | 73 | 1.57 | $366,304 | $224,042 |
| 2017 | 598 | 2,197 | 74 | 1.54 | $455,988 | $254,061 |
| 2016 | 623 | 2,198 | 74 | 1.41 | $324,887 | $196,904 |
| 2015 | 623 | 2,291 | 74 | 1.54 | $329,207 | $197,572 |
| 2014 | 503 | 1,946 | 74 | 1.30 | $236,651 | $137,745 |
| 2013 | 554 | 3,425 | 74 | 1.43 | $490,490 | $218,389 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 12 services
| Injection of biodegradable material next to prostate | 11 | $32,431 | $2,948 |
| Short return visit (20+ min) | 285 | $24,940 | $52 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 21 | $17,776 | None |
| New patient visit (45+ min) | 84 | $10,684 | $127 |
| Short return visit | 126 | $8,384 | $47 |
| Diagnostic exam of bladder and urethra using an endoscope | 34 | $8,141 | $194 |
| Shock wave crushing of kidney stones | 14 | $7,905 | $565 |
| Return visit (30+ min) | 66 | $6,765 | $97 |
| Simple bladder irrigation and/or instillation | 13 | $1,371 | $72 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 21 | $1,225 | $25 |
| New patient visit (30+ min) | 13 | $1,162 | $89 |
| Subsequent nursing facility care with straightforward level of medical decision making, per day at least 10 minutes | 14 | $331 | $18 |
2022: 18 services
| Short return visit (20+ min) | 310 | $26,607 | $54 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 27 | $25,193 | None |
| Short return visit | 149 | $12,343 | $43 |
| Diagnostic exam of bladder and urethra using an endoscope | 34 | $10,174 | $196 |
| New patient visit (45+ min) | 79 | $9,446 | $120 |
| Return visit (30+ min) | 88 | $8,670 | $87 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 12 | $7,345 | $612 |
| Shock wave crushing of kidney stones | 11 | $6,153 | $513 |
| Biopsy of prostate gland | 23 | $4,520 | $197 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 13 | $2,268 | $162 |
| Simple bladder irrigation and/or instillation | 22 | $2,172 | $70 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 28 | $1,558 | $27 |
| Simple insertion of temporary bladder tube | 12 | $1,177 | $51 |
| Ultrasound scan of pelvic region through rectum | 23 | $686 | $29 |
| Subsequent nursing facility care with straightforward level of medical decision making, per day at least 10 minutes | 19 | $672 | $34 |
| Subsequent nursing facility care with straightforward level of medical decision making, per day 20 minutes or more | 11 | $386 | $35 |
| Ultrasound scan of pelvic region through rectum | 12 | $370 | $28 |
| Online digital evaluation and management service for an established patient for up to 7 days, total time 5-10 minutes | 13 | $118 | $9 |
2021: 14 services
| Short return visit | 293 | $22,191 | $43 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 24 | $20,914 | None |
| Short return visit (20+ min) | 204 | $16,475 | $59 |
| Diagnostic exam of bladder and urethra using an endoscope | 55 | $12,673 | $192 |
| New patient visit (45+ min) | 88 | $10,742 | $122 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 12 | $7,326 | $610 |
| Return visit (30+ min) | 69 | $7,105 | $91 |
| Biopsy of prostate gland | 23 | $4,104 | $171 |
| Simple bladder irrigation and/or instillation | 25 | $2,031 | $70 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 24 | $1,389 | $27 |
| Simple insertion of temporary bladder tube | 12 | $1,173 | $56 |
| Ultrasound scan of pelvic region through rectum | 18 | $861 | $43 |
| Subsequent nursing facility care with straightforward level of medical decision making, per day at least 10 minutes | 22 | $725 | $30 |
| Subsequent nursing facility care with straightforward level of medical decision making, per day 20 minutes or more | 11 | $573 | $52 |
2020: 17 services
| Leuprolide acetate (for depot suspension), 7.5 mg | 26 | $38,063 | None |
| Short return visit | 297 | $17,738 | $37 |
| Diagnostic exam of bladder and urethra using an endoscope | 46 | $9,809 | $169 |
| New patient visit (45+ min) | 72 | $9,095 | $126 |
| Short return visit (20+ min) | 120 | $8,203 | $60 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 12 | $7,012 | $584 |
| Return visit (30+ min) | 46 | $3,455 | $75 |
| Simple bladder irrigation and/or instillation | 23 | $2,847 | $66 |
| Injection of drug or substance under skin or into muscle | 14 | $2,425 | $11 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 19 | $2,303 | $110 |
| Biopsy of prostate gland | 14 | $2,111 | $151 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 25 | $1,667 | $25 |
| New patient visit (30+ min) | 13 | $1,008 | $78 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 12 | $919 | $51 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 31 | $901 | $18 |
| Ultrasound scan of pelvic region through rectum | 12 | $874 | $58 |
| Subsequent nursing facility care with straightforward level of medical decision making, per day at least 10 minutes | 22 | $778 | $31 |
2019: 22 services
| Leuprolide acetate (for depot suspension), 7.5 mg | 34 | $52,555 | None |
| Injection of biodegradable material next to prostate | 12 | $39,518 | $3,293 |
| Short return visit | 373 | $23,268 | $36 |
| Insertion of lower leg neurostimulator electrode | 11 | $12,923 | $120 |
| New patient visit (45+ min) | 99 | $11,629 | $117 |
| Short return visit (20+ min) | 156 | $9,819 | $54 |
| Diagnostic exam of bladder and urethra using an endoscope | 47 | $9,360 | $164 |
| Shock wave crushing of kidney stones | 11 | $7,175 | $552 |
| Biopsy of prostate gland | 30 | $4,452 | $148 |
| Return visit (30+ min) | 40 | $3,252 | $79 |
| Injection of drug or substance under skin or into muscle | 13 | $3,120 | $15 |
| Simple bladder irrigation and/or instillation | 29 | $2,974 | $62 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 34 | $2,237 | $27 |
| Subsequent nursing facility care with straightforward level of medical decision making, per day 20 minutes or more | 36 | $2,217 | $53 |
| New patient visit (60+ min) | 13 | $1,736 | $134 |
| Subsequent nursing facility care with straightforward level of medical decision making, per day at least 10 minutes | 39 | $1,669 | $33 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 15 | $1,636 | $109 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 11 | $1,629 | $148 |
| Simple insertion of temporary bladder tube | 11 | $1,502 | $56 |
| Ultrasound scan of pelvic region through rectum | 29 | $1,141 | $39 |
| New patient visit (30+ min) | 15 | $1,130 | $75 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 38 | $961 | $19 |
2018: 20 services
| Leuprolide acetate (for depot suspension), 7.5 mg | 39 | $50,301 | None |
| Short return visit | 437 | $28,922 | $37 |
| New patient visit (45+ min) | 149 | $17,041 | $114 |
| Diagnostic exam of bladder and urethra using an endoscope | 53 | $10,185 | $143 |
| Short return visit (20+ min) | 132 | $7,412 | $48 |
| Shock wave crushing of kidney stones | 11 | $6,681 | $607 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 11 | $6,421 | $584 |
| Biopsy of prostate gland | 30 | $4,714 | $147 |
| Simple bladder irrigation and/or instillation | 30 | $3,512 | $60 |
| New patient visit (60+ min) | 23 | $2,840 | $123 |
| Injection of drug or substance under skin or into muscle | 14 | $2,747 | $18 |
| Return visit (30+ min) | 30 | $2,245 | $68 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 38 | $2,152 | $28 |
| Long return visit (40+ min) | 19 | $2,146 | $107 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 14 | $1,985 | $142 |
| Simple insertion of temporary bladder tube | 11 | $1,903 | $53 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 14 | $1,515 | $101 |
| Ultrasound scan of pelvic region through rectum | 26 | $1,265 | $45 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 34 | $813 | $19 |
| Subsequent nursing facility care with straightforward level of medical decision making, per day at least 10 minutes | 11 | $500 | $36 |
2017: 19 services
| Insertion of implant in urethra within prostate gland using an endoscope, each additional implant | 12 | $57,898 | $965 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 33 | $47,654 | None |
| Short return visit | 430 | $28,997 | $36 |
| New patient visit (45+ min) | 136 | $15,068 | $111 |
| Insertion of implant in urethra within prostate gland using an endoscope, 1 implant | 12 | $14,174 | $1,181 |
| Diagnostic exam of bladder and urethra using an endoscope | 63 | $10,854 | $143 |
| Shock wave crushing of kidney stones | 18 | $10,537 | $502 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 11 | $6,819 | $620 |
| Short return visit (20+ min) | 103 | $5,937 | $50 |
| Biopsy of prostate gland | 26 | $3,916 | $151 |
| New patient visit (60+ min) | 23 | $3,012 | $131 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 33 | $2,271 | $29 |
| Return visit (30+ min) | 34 | $2,229 | $60 |
| Simple insertion of temporary bladder tube | 12 | $1,590 | $48 |
| Simple bladder irrigation and/or instillation | 23 | $1,549 | $53 |
| Long return visit (40+ min) | 15 | $1,497 | $94 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 12 | $1,244 | $104 |
| Ultrasound scan of pelvic region through rectum | 24 | $897 | $37 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 32 | $793 | $19 |
2016: 18 services
| Leuprolide acetate (for depot suspension), 7.5 mg | 34 | $53,864 | None |
| Short return visit | 456 | $29,860 | $35 |
| New patient visit (45+ min) | 140 | $14,585 | $104 |
| Diagnostic exam of bladder and urethra using an endoscope | 67 | $11,375 | $142 |
| Shock wave crushing of kidney stones | 13 | $7,313 | $522 |
| Surgical exposure of prostate gland for radiation therapy | 12 | $6,767 | $564 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 12 | $6,717 | $560 |
| Short return visit (20+ min) | 116 | $5,606 | $41 |
| Simple bladder irrigation and/or instillation | 44 | $3,892 | $60 |
| Biopsy of prostate gland | 25 | $3,495 | $140 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 34 | $2,114 | $28 |
| Return visit (30+ min) | 23 | $1,545 | $64 |
| Simple insertion of temporary bladder tube | 16 | $1,442 | $50 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 15 | $1,429 | $95 |
| Long return visit (40+ min) | 12 | $1,261 | $97 |
| Ultrasonic guidance for needle placement | 17 | $951 | $56 |
| Ultrasound scan of pelvic region through rectum | 12 | $677 | $56 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 25 | $480 | $17 |
2015: 18 services
| Leuprolide acetate (for depot suspension), 7.5 mg | 39 | $62,470 | None |
| Short return visit | 439 | $25,703 | $34 |
| New patient visit (45+ min) | 130 | $13,926 | $107 |
| Short return visit (20+ min) | 175 | $11,351 | $50 |
| Shock wave crushing of kidney stones | 15 | $8,223 | $514 |
| Diagnostic exam of bladder and urethra using an endoscope | 40 | $7,548 | $145 |
| Biopsy of prostate gland | 28 | $4,196 | $150 |
| Simple insertion of temporary bladder tube | 19 | $2,675 | $52 |
| Return visit (30+ min) | 39 | $2,675 | $67 |
| Simple bladder irrigation and/or instillation | 33 | $2,517 | $59 |
| Long return visit (40+ min) | 22 | $2,259 | $90 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 39 | $2,030 | $26 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 12 | $1,578 | $131 |
| Ultrasonic guidance for needle placement | 29 | $1,562 | $54 |
| Ultrasound scan of pelvic region through rectum | 17 | $1,162 | $68 |
| New patient visit (30+ min) | 12 | $894 | $74 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 11 | $225 | $19 |
| Electronic assessment of bladder emptying | 14 | $183 | $13 |
2014: 15 services
| Leuprolide acetate (for depot suspension), 7.5 mg | 29 | $43,191 | None |
| Short return visit | 341 | $19,091 | $27 |
| New patient visit (45+ min) | 82 | $7,849 | $96 |
| Diagnostic exam of bladder and urethra using an endoscope | 49 | $7,620 | $131 |
| Return visit (30+ min) | 102 | $5,227 | $49 |
| Short return visit (20+ min) | 96 | $4,651 | $43 |
| Biopsy of prostate gland | 21 | $2,745 | $125 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 30 | $1,947 | $27 |
| Simple bladder irrigation and/or instillation | 27 | $1,896 | $56 |
| Long return visit (40+ min) | 21 | $1,695 | $81 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 13 | $1,557 | $120 |
| Simple insertion of temporary bladder tube | 17 | $1,536 | $48 |
| Ultrasonic guidance for needle placement | 20 | $1,399 | $67 |
| Ultrasound scan of pelvic region through rectum | 12 | $742 | $57 |
| Electronic assessment of bladder emptying | 15 | $208 | $11 |
2013: 18 services
| Leuprolide acetate (for depot suspension), 7.5 mg | 38 | $57,193 | None |
| Short return visit (20+ min) | 382 | $33,777 | $54 |
| Diagnostic exam of bladder and urethra using an endoscope | 41 | $9,949 | $169 |
| Short return visit | 168 | $8,317 | $35 |
| New patient visit (45+ min) | 67 | $7,975 | $119 |
| Ultrasonic guidance for needle placement | 31 | $6,366 | $199 |
| Shock wave crushing of kidney stones | 11 | $5,993 | $499 |
| Return visit (30+ min) | 53 | $5,786 | $85 |
| Biopsy of prostate gland | 30 | $5,652 | $182 |
| New patient visit (30+ min) | 42 | $3,625 | $86 |
| Long return visit (40+ min) | 22 | $3,003 | $120 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 38 | $2,525 | $29 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 19 | $2,351 | $112 |
| Ultrasound scan of pelvic region through rectum | 31 | $2,165 | $68 |
| Simple insertion of temporary bladder tube | 11 | $1,980 | $64 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 12 | $702 | $32 |
| Electronic assessment of bladder emptying | 32 | $495 | $13 |
| Urinalysis, manual test | 12 | $49 | $3 |
Medicaid work
$7,379 in 2024
Medicaid paid $7,379 for 319 billed services this clinician did in 2024, up to 34 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Short return visit (20+ min) | 306 | $7,090 |
| Short return visit | 13 | $290 |
| 2024 | 319 | 2 | 34 | $7,379 |
| 2023 | 380 | 2 | 30 | $11,271 |
| 2022 | 549 | 3 | 39 | $13,642 |
| 2021 | 486 | 3 | 38 | $10,691 |
| 2020 | 372 | 3 | 38 | $7,280 |
| 2019 | 310 | 2 | 32 | $9,720 |
| 2018 | 314 | 2 | 42 | $13,813 |
See the largest Medicaid services in earlier years
2023
| Short return visit (20+ min) | 326 | $6,604 |
| New patient visit (45+ min) | 54 | $4,668 |
2022
| Short return visit (20+ min) | 343 | $6,212 |
| New patient visit (45+ min) | 61 | $5,330 |
| Short return visit | 145 | $2,100 |
2021
| Short return visit | 328 | $4,826 |
| New patient visit (45+ min) | 38 | $3,717 |
| Short return visit (20+ min) | 120 | $2,149 |
2020
| Short return visit | 332 | $5,644 |
| New patient visit (45+ min) | 13 | $979 |
| Short return visit (20+ min) | 27 | $657 |
2019
| Short return visit | 283 | $6,933 |
| New patient visit (45+ min) | 27 | $2,787 |
2018
| New patient visit (45+ min) | 77 | $8,007 |
| Short return visit | 237 | $5,806 |
Drugs they prescribed that Part D paid
$222,376
Pharmacies billed $222,376 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 2% of their Part D prescriptions (32 of 1,346) in 2024. Above the middle of the specialty; the typical urology clinician is at 2%.
1,179 generic and 167 brand-name prescriptions · $222,376 in drug cost · 221 antibiotic prescriptions to 109 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Myrbetriq | 122 | $86,314 | $707 |
| Oxybutynin Chloride Er | 203 | $5,701 | $28 |
| Tamsulosin | 416 | $5,554 | $13 |
| Testosterone Cypionate | 38 | $2,312 | $61 |
| Bicalutamide | 60 | $1,941 | $32 |
See all 14 drugs
| Myrbetriq | 122 | $86,314 | $707 |
| Oxybutynin Chloride Er | 203 | $5,701 | $28 |
| Tamsulosin | 416 | $5,554 | $13 |
| Testosterone Cypionate | 38 | $2,312 | $61 |
| Bicalutamide | 60 | $1,941 | $32 |
| Dutasteride | 19 | $1,754 | $92 |
| Testosterone | 23 | $1,700 | $74 |
| Solifenacin | 22 | $1,640 | $75 |
| Finasteride | 56 | $649 | $12 |
| Sulfamethoxazole-Trimethoprim | 115 | $257 | $2 |
| Ciprofloxacin | 44 | $166 | $4 |
| Hydrocodone-Acetaminophen | 22 | $147 | $7 |
| Amoxicillin-Clavulanate Potass | 17 | $88 | $5 |
| Doxycycline Hyclate | 11 | $68 | $6 |
Year by year
| 2024 | 1,346 | 304 | 2% (32) | 12% | $222,376 |
| 2023 | 1,372 | 296 | 3% (35) | None | $235,536 |
| 2022 | 1,304 | 288 | 4% (58) | None | $302,848 |
| 2021 | 1,404 | 330 | 5% (71) | 10% | $287,066 |
| 2020 | 1,450 | 299 | 4% (63) | None | $306,777 |
| 2019 | 1,548 | 348 | 5% (78) | None | $374,568 |
| 2018 | 1,663 | 352 | 4% (74) | 22% | $373,904 |
| 2017 | 1,524 | 345 | 5% (81) | 22% | $413,871 |
| 2016 | 1,730 | 374 | 6% (95) | None | $250,213 |
| 2015 | 1,710 | 373 | 4% (65) | None | $248,187 |
| 2014 | 1,775 | 369 | 3% (46) | None | $256,245 |
| 2013 | 1,913 | 364 | 5% (91) | None | $224,532 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 15 drugs
| Myrbetriq | 129 | $101,875 | $790 |
| Tamsulosin | 374 | $12,311 | $33 |
| Testosterone | 26 | $11,987 | $461 |
| Oxybutynin Chloride Er | 171 | $7,953 | $47 |
| Solifenacin | 54 | $5,835 | $108 |
| Bicalutamide | 72 | $3,576 | $50 |
| Finasteride | 79 | $2,208 | $28 |
| Testosterone Cypionate | 25 | $1,455 | $58 |
| Sulfamethoxazole-Trimethoprim | 136 | $576 | $4 |
| Oxybutynin Chloride | 13 | $458 | $35 |
| Dutasteride | 12 | $412 | $34 |
| Ciprofloxacin | 49 | $385 | $8 |
| Amoxicillin-Clavulanate Potass | 37 | $300 | $8 |
| Hydrocodone-Acetaminophen | 27 | $298 | $11 |
| Gabapentin | 14 | $115 | $8 |
2022: 15 drugs
| Myrbetriq | 112 | $92,679 | $827 |
| Oxybutynin Chloride Er | 155 | $10,147 | $65 |
| Testosterone | 18 | $7,935 | $441 |
| Tamsulosin | 337 | $7,809 | $23 |
| Bicalutamide | 86 | $6,382 | $74 |
| Solifenacin | 56 | $4,195 | $75 |
| Finasteride | 91 | $1,659 | $18 |
| Testosterone Cypionate | 28 | $1,561 | $56 |
| Oxybutynin Chloride | 21 | $1,542 | $73 |
| Hydrocodone-Acetaminophen | 55 | $845 | $15 |
| Sulfamethoxazole-Trimethoprim | 148 | $568 | $4 |
| Doxazosin Mesylate | 21 | $561 | $27 |
| Ciprofloxacin | 31 | $176 | $6 |
| Amoxicillin-Clavulanate Potass | 18 | $132 | $7 |
| Alendronate | 12 | $115 | $10 |
2021: 20 drugs
| Myrbetriq | 108 | $106,898 | $990 |
| Tamsulosin | 343 | $8,838 | $26 |
| Rimso-50 | 11 | $7,150 | $650 |
| Bicalutamide | 100 | $6,909 | $69 |
| Oxybutynin Chloride Er | 136 | $5,810 | $43 |
| Solifenacin | 72 | $5,539 | $77 |
| Finasteride | 105 | $2,496 | $24 |
| Oxybutynin Chloride | 24 | $1,650 | $69 |
| Testosterone Cypionate | 25 | $1,387 | $55 |
| Nitrofurantoin Mono-Macro | 18 | $1,058 | $59 |
| Dutasteride | 11 | $722 | $66 |
| Doxazosin Mesylate | 19 | $657 | $35 |
| Sulfamethoxazole-Trimethoprim | 159 | $604 | $4 |
| Hydrocodone-Acetaminophen | 47 | $571 | $12 |
| Oxycodone-Acetaminophen | 17 | $402 | $24 |
| Doxycycline Hyclate | 11 | $272 | $25 |
| Terazosin | 18 | $240 | $13 |
| Ciprofloxacin | 35 | $192 | $5 |
| Amoxicillin-Clavulanate Potass | 16 | $120 | $7 |
| Alendronate | 15 | $108 | $7 |
2020: 19 drugs
| Myrbetriq | 142 | $110,424 | $778 |
| Testosterone | 14 | $10,747 | $768 |
| Rimso-50 | 16 | $10,400 | $650 |
| Tamsulosin | 341 | $8,042 | $24 |
| Solifenacin | 84 | $5,824 | $69 |
| Oxybutynin Chloride Er | 97 | $5,384 | $56 |
| Bicalutamide | 54 | $2,929 | $54 |
| Finasteride | 115 | $2,821 | $25 |
| Testosterone Cypionate | 38 | $2,489 | $65 |
| Dutasteride | 17 | $2,352 | $138 |
| Nitrofurantoin Mono-Macro | 33 | $2,311 | $70 |
| Oxybutynin Chloride | 35 | $1,811 | $52 |
| Oxycodone-Acetaminophen | 20 | $573 | $29 |
| Sulfamethoxazole-Trimethoprim | 163 | $515 | $3 |
| Doxazosin Mesylate | 20 | $427 | $21 |
| Terazosin | 17 | $396 | $23 |
| Hydrocodone-Acetaminophen | 36 | $343 | $10 |
| Ciprofloxacin | 49 | $265 | $5 |
| Amoxicillin-Clavulanate Potass | 26 | $232 | $9 |
2019: 18 drugs
| Xtandi | 11 | $135,844 | $12,349 |
| Vesicare | 98 | $71,785 | $733 |
| Myrbetriq | 93 | $65,680 | $706 |
| Tamsulosin | 395 | $8,988 | $23 |
| Rimso-50 | 14 | $8,838 | $631 |
| Solifenacin | 58 | $6,356 | $110 |
| Oxybutynin Chloride Er | 83 | $4,165 | $50 |
| Finasteride | 133 | $3,322 | $25 |
| Oxybutynin Chloride | 54 | $2,466 | $46 |
| Bicalutamide | 69 | $2,220 | $32 |
| Nitrofurantoin Mono-Macro | 24 | $2,200 | $92 |
| Testosterone Cypionate | 31 | $1,691 | $55 |
| Dutasteride | 22 | $1,676 | $76 |
| Hydrocodone-Acetaminophen | 65 | $644 | $10 |
| Terazosin | 26 | $581 | $22 |
| Sulfamethoxazole-Trimethoprim | 131 | $503 | $4 |
| Doxazosin Mesylate | 16 | $475 | $30 |
| Ciprofloxacin | 59 | $333 | $6 |
2018: 20 drugs
| Vesicare | 143 | $89,888 | $629 |
| Myrbetriq | 130 | $73,432 | $565 |
| Elmiron | 15 | $26,078 | $1,739 |
| Androgel | 17 | $23,273 | $1,369 |
| Tamsulosin | 400 | $10,836 | $27 |
| Finasteride | 170 | $4,091 | $24 |
| Oxybutynin Chloride | 72 | $3,366 | $47 |
| Oxybutynin Chloride Er | 62 | $3,132 | $51 |
| Bicalutamide | 77 | $2,405 | $31 |
| Dutasteride | 18 | $1,217 | $68 |
| Nitrofurantoin Mono-Macro | 16 | $741 | $46 |
| Amoxicillin-Clavulanate Potass | 38 | $715 | $19 |
| Hydrocodone-Acetaminophen | 53 | $706 | $13 |
| Testosterone Cypionate | 27 | $634 | $23 |
| Sulfamethoxazole-Trimethoprim | 144 | $495 | $3 |
| Terazosin | 29 | $466 | $16 |
| Zoledronic Acid | 13 | $301 | $23 |
| Ciprofloxacin | 49 | $297 | $6 |
| Levofloxacin | 11 | $123 | $11 |
| Acetaminophen-Codeine | 15 | $117 | $8 |
2017: 20 drugs
| Vesicare | 161 | $85,615 | $532 |
| Myrbetriq | 82 | $43,345 | $529 |
| Elmiron | 19 | $24,039 | $1,265 |
| Androgel | 18 | $23,199 | $1,289 |
| Tamsulosin | 376 | $12,822 | $34 |
| Toviaz | 12 | $6,174 | $514 |
| Finasteride | 164 | $3,914 | $24 |
| Oxybutynin Chloride | 61 | $3,856 | $63 |
| Dutasteride | 29 | $2,648 | $91 |
| Bicalutamide | 57 | $1,904 | $33 |
| Nitrofurantoin Mono-Macro | 30 | $1,769 | $59 |
| Testosterone Cypionate | 25 | $836 | $33 |
| Terazosin | 36 | $546 | $15 |
| Doxazosin Mesylate | 11 | $523 | $48 |
| Amoxicillin-Clavulanate Potass | 26 | $435 | $17 |
| Hydrocodone-Acetaminophen | 63 | $394 | $6 |
| Sulfamethoxazole-Trimethoprim | 130 | $374 | $3 |
| Ciprofloxacin | 52 | $274 | $5 |
| Cephalexin | 12 | $111 | $9 |
| Acetaminophen-Codeine | 13 | $97 | $7 |
2016: 19 drugs
| Vesicare | 196 | $79,067 | $403 |
| Myrbetriq | 114 | $48,978 | $430 |
| Elmiron | 30 | $24,758 | $825 |
| Tamsulosin | 471 | $18,696 | $40 |
| Androgel | 14 | $13,219 | $944 |
| Toviaz | 16 | $9,347 | $584 |
| Dutasteride | 39 | $6,553 | $168 |
| Rapaflo | 12 | $5,125 | $427 |
| Finasteride | 159 | $3,373 | $21 |
| Oxybutynin Chloride | 63 | $3,341 | $53 |
| Bicalutamide | 80 | $3,003 | $38 |
| Nitrofurantoin Mono-Macro | 30 | $2,734 | $91 |
| Oxybutynin Chloride Er | 19 | $1,232 | $65 |
| Hydrocodone-Acetaminophen | 73 | $1,052 | $14 |
| Sulfamethoxazole-Trimethoprim | 172 | $571 | $3 |
| Amoxicillin-Clavulanate Potass | 12 | $361 | $30 |
| Terazosin | 21 | $331 | $16 |
| Ciprofloxacin | 53 | $310 | $6 |
| Cephalexin | 13 | $68 | $5 |
2015: 19 drugs
| Vesicare | 185 | $71,587 | $387 |
| Avodart | 115 | $29,831 | $259 |
| Myrbetriq | 63 | $27,923 | $443 |
| Tamsulosin | 466 | $23,382 | $50 |
| Elmiron | 36 | $21,742 | $604 |
| Androgel | 24 | $19,587 | $816 |
| Toviaz | 23 | $9,161 | $398 |
| Rapaflo | 11 | $5,022 | $457 |
| Bicalutamide | 86 | $4,073 | $47 |
| Oxybutynin Chloride | 79 | $4,051 | $51 |
| Finasteride | 175 | $3,605 | $21 |
| Nitrofurantoin Mono-Macro | 28 | $2,560 | $91 |
| Oxybutynin Chloride Er | 25 | $2,346 | $94 |
| Doxazosin Mesylate | 14 | $781 | $56 |
| Sulfamethoxazole-Trimethoprim | 126 | $460 | $4 |
| Ciprofloxacin | 39 | $326 | $8 |
| Hydrocodone-Acetaminophen | 32 | $291 | $9 |
| Terazosin | 24 | $278 | $12 |
| Acetaminophen-Codeine | 16 | $93 | $6 |
2014: 19 drugs
| Vesicare | 241 | $75,424 | $313 |
| Avodart | 172 | $43,020 | $250 |
| Myrbetriq | 67 | $24,509 | $366 |
| Androgel | 24 | $17,488 | $729 |
| Elmiron | 22 | $13,916 | $633 |
| Tamsulosin | 402 | $12,540 | $31 |
| Tolterodine Tartrate Er | 24 | $9,490 | $395 |
| Toviaz | 19 | $7,098 | $374 |
| Bicalutamide | 98 | $6,690 | $68 |
| Rapaflo | 21 | $6,071 | $289 |
| Oxybutynin Chloride | 78 | $4,224 | $54 |
| Finasteride | 154 | $3,470 | $23 |
| Nitrofurantoin Mono-Macro | 24 | $3,140 | $131 |
| Doxazosin Mesylate | 28 | $1,335 | $48 |
| Sulfamethoxazole-Trimethoprim | 154 | $631 | $4 |
| Terazosin | 23 | $343 | $15 |
| Hydrocodone-Acetaminophen | 37 | $325 | $9 |
| Allopurinol | 12 | $255 | $21 |
| Ciprofloxacin | 35 | $200 | $6 |
2013: 21 drugs
| Vesicare | 219 | $52,248 | $239 |
| Avodart | 198 | $39,371 | $199 |
| Androgel | 29 | $18,577 | $641 |
| Elmiron | 24 | $17,755 | $740 |
| Detrol La | 26 | $15,219 | $585 |
| Bicalutamide | 127 | $11,961 | $94 |
| Myrbetriq | 37 | $11,895 | $321 |
| Tamsulosin | 439 | $11,581 | $26 |
| Rapaflo | 36 | $7,548 | $210 |
| Finasteride | 163 | $5,436 | $33 |
| Axiron | 11 | $4,406 | $401 |
| Nitrofurantoin Mono-Macro | 32 | $3,378 | $106 |
| Oxybutynin Chloride Er | 16 | $2,793 | $175 |
| Oxybutynin Chloride | 64 | $2,273 | $36 |
| Hydrocodone-Acetaminophen | 82 | $776 | $9 |
| Sulfamethoxazole-Trimethoprim | 159 | $639 | $4 |
| Testosterone Cypionate | 13 | $551 | $42 |
| Doxazosin Mesylate | 28 | $544 | $19 |
| Terazosin | 39 | $480 | $12 |
| Allopurinol | 11 | $171 | $16 |
| Ciprofloxacin | 23 | $109 | $5 |
Money from drug and device companies
$532 in 2025
| 2025 | 10 | 19 | None | $532 |
| 2024 | 7 | 19 | None | $530 |
| 2023 | 9 | 16 | None | $400 |
| 2022 | 10 | 23 | None | $534 |
| 2021 | 6 | 11 | None | $287 |
| 2020 | 3 | 4 | None | $83 |
| 2019 | 7 | 10 | None | $313 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Teleflex | Urolift | $118 | 3 payments
|
| Janssen Biotech | Erleada | $68 | 2 payments
|
| Abbvie | Lupron Depot | $64 | 3 payments
|
| ConvaTec | Gentlecath | $53 | 2 payments
|
| Ferring Pharmaceuticals | Adstiladrin | $51 | 2 payments
|
| Procept Biorobotics | Aquabeam Robotic System | $40 | 1 payment
|
See all 19 published payments
| Ferring Pharmaceuticals | Meals · 2025-12-12 | Adstiladrin | $28 |
| Janssen Biotech | Meals · 2025-12-04 | Erleada | $42 |
| Abbvie | Meals · 2025-11-24 | Lupron Depot | $25 |
| AstraZeneca Pharmaceuticals LP | Education · 2025-11-19 | Imfinzi | $35 |
| Dendreon Pharmaceuticals | Meals · 2025-11-17 | Provenge | $17 |
| Dendreon Pharmaceuticals | Meals · 2025-11-13 | Provenge | $22 |
| Procept Biorobotics | Meals · 2025-10-30 | Aquabeam Robotic System | $40 |
| Pfizer | Meals · 2025-08-14 | Xtandi | $23 |
| Teleflex | Meals · 2025-08-08 | Urolift | $44 |
| Teleflex | Meals · 2025-07-07 | Barrigel | $28 |
| C. R. Bard Inc. & Subsidiaries | Meals · 2025-07-03 | Bard Urinary Drainage Bag | $26 |
| Abbvie | Meals · 2025-07-02 | Lupron Depot | $20 |
| Teleflex | Meals · 2025-06-18 | Urolift | $47 |
| Janssen Biotech | Meals · 2025-06-05 | Erleada | $26 |
| Ferring Pharmaceuticals | Meals · 2025-05-29 | Adstiladrin | $22 |
| ConvaTec | Meals · 2025-04-10 | Gentlecath | $24 |
| Abbvie | Meals · 2025-03-27 | Lupron Depot | $20 |
| ConvaTec | Meals · 2025-03-11 | Gentlecath | $29 |
| Pfizer | Meals · 2025-02-13 | Xtandi | $14 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $530
| Astellas Pharma US | Veozah | $157 | 4 payments
|
| Abbvie | Lupron Depot | $153 | 9 payments
|
| Janssen Biotech | Erleada | $76 | 2 payments
|
| Boston Scientific | Spaceoar Vue System - 10ml | $50 | 1 payment
|
| Dendreon Pharmaceuticals | Provenge | $44 | 1 payment
|
| Immunitybio | Anktiva | $31 | 1 payment
|
| Pfizer | Xtandi | $19 | 1 payment
|
2023: $400
| Astellas Pharma US | Myrbetriq | $89 | 4 payments
|
| Merck Sharp & Dohme | Keytruda | $85 | 3 payments
|
| Sumitomo Pharma America | Orgovyx | $50 | 2 payments
|
| Pfizer | Xtandi | $42 | 2 payments
|
| Teleflex | Urolift | $35 | 1 payment
|
| AngioDynamics | Nanoknife | $33 | 1 payment
|
| Janssen Biotech | Erleada | $30 | 1 payment
|
| AbbVie | Lupron Depot | $19 | 1 payment
|
| IsoRay | Brachytherapy Source | $17 | 1 payment
|
2022: $534
| Astellas Pharma US | Myrbetriq | $149 | 8 payments
|
| Janssen Biotech | Erleada | $87 | 3 payments
|
| UroGen Pharma | Jelmyto | $68 | 2 payments
|
| Abbvie | Lupron Depot | $60 | 3 payments
|
| Olympus America | Itind System | $42 | 2 payments
|
| Boston Scientific | Rezum Generator | $36 | 1 payment
|
| Myriad Genetic Laboratories | Prolaris | $35 | 1 payment
|
| Photocure | Cysview | $23 | 1 payment
|
| Accord Healthcare | Camcevi | $19 | 1 payment
|
| Allergan | Botox | $17 | 1 payment
|
2021: $287
| Janssen Biotech | Erleada | $114 | 4 payments
|
| AbbVie | Lupron Depot | $74 | 3 payments
|
| Hollister | Infyna Chic | $30 | 1 payment
|
| Astellas Pharma US | Myrbetriq | $25 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $22 | 1 payment
|
| Allergan | Botox | $21 | 1 payment
|
2020: $83
| AbbVie | Lupron Depot | $38 | 2 payments
|
| Astellas Pharma US | Myrbetriq | $25 | 1 payment
|
| Allergan | Botox | $21 | 1 payment
|
2019: $313
| Genzyme | Jevtana | $125 | 1 payment
|
| Allergan | Botox | $60 | 3 payments
|
| Endo Pharmaceuticals | Aveed | $44 | 2 payments
|
| Janssen Biotech | Erleada | $30 | 1 payment
|
| Bard Access Systems | None | $22 | 1 payment
|
| Astellas Pharma US | Xtandi | $21 | 1 payment
|
| AbbVie | Lupron Depot | $11 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 75.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1265533426
- Licence
- CA G23121California G23121: Current · expires 2027-02-28
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 174400000X (174400000X)
- Mailing address
- 2089 Vale Rd, Suite 25, San Pablo, CA, 94806
- NPI first listed
- 2006-09-26
- NPI last updated
- 2007-07-08
This is when the NPI record was last certified, not a medical board exam.